triumph 1 trial retatrutide just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Finished 18 month Triumph 1
Description
The research utilized specialty pharmacy claims data from the Earnest Phoenix dataset
The personalized medical weight loss options offered by our providers may include GLP-1 medications such as Semaglutide or Liraglutide, depending on individual needs and availability
Is Shed Cost safe, and what patients should avoid GLP-1 treatment altogether
Overweight, obesity, youth, and health-risk behaviors
Underactive thyroid (hypothyroidism)
Many people unconsciously increase portion sizes as side effects resolve, without realizing their intake has increased
